Related Experiment Video
Updated: May 22, 2026
12:24
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
[Tumor markers for hepatocellular carcinoma]
Ryosuke Tateishi1, Kenichiro Enooku, Shuichiro Shiina
1Department of Gastroenterology, The University of Tokyo Graduate School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 25, 2012
Summary
Hepatocellular carcinoma (HCC) surveillance relies on three key tumor markers: alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonists-II (PIVKA-II), and AFP-L3. Each marker offers unique diagnostic and prognostic value in HCC management.
Area of Science:
- Oncology
- Biochemistry
- Clinical Diagnostics
Context:
- Hepatocellular carcinoma (HCC) management in Japan utilizes three primary tumor markers.
- Alpha-fetoprotein (AFP) has limitations in specificity but is crucial for treatment evaluation and prognosis.
- Protein induced by vitamin K absence or antagonists-II (PIVKA-II) and AFP-L3 offer distinct advantages.
Purpose:
- To highlight the indispensable roles of AFP, PIVKA-II, and AFP-L3 in HCC clinical practice.
- To underscore the complementary nature of these markers in surveillance, diagnosis, and prognosis.
- To emphasize their utility in predicting outcomes and guiding treatment decisions.
Summary:
- AFP, PIVKA-II, and AFP-L3 are essential tumor markers for hepatocellular carcinoma (HCC).
- AFP is widely used despite specificity issues, while PIVKA-II predicts microvascular invasion and AFP-L3 indicates poor prognosis.
- These markers are vital for comprehensive HCC patient management, from initial surveillance to long-term prognosis.
Impact:
- Improved accuracy in HCC diagnosis and prognosis prediction.
- Enhanced clinical decision-making for HCC treatment strategies.
- Better patient outcomes through comprehensive marker utilization in HCC care.
